BR112012008193A2 - composições compreendendo um inibidor de receptor dopaminérgico d2, bem como o uso do preferido inibidor - Google Patents
composições compreendendo um inibidor de receptor dopaminérgico d2, bem como o uso do preferido inibidorInfo
- Publication number
- BR112012008193A2 BR112012008193A2 BR112012008193A BR112012008193A BR112012008193A2 BR 112012008193 A2 BR112012008193 A2 BR 112012008193A2 BR 112012008193 A BR112012008193 A BR 112012008193A BR 112012008193 A BR112012008193 A BR 112012008193A BR 112012008193 A2 BR112012008193 A2 BR 112012008193A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- inhibitor
- disease
- well
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 108091006082 receptor inhibitors Proteins 0.000 title abstract 2
- 230000003291 dopaminomimetic effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 229960003878 haloperidol Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23026409P | 2009-07-31 | 2009-07-31 | |
| PCT/CA2010/001185 WO2011011886A1 (en) | 2009-07-31 | 2010-07-30 | Compositions and methods for treating parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012008193A2 true BR112012008193A2 (pt) | 2016-03-01 |
Family
ID=43528672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012008193A BR112012008193A2 (pt) | 2009-07-31 | 2010-07-30 | composições compreendendo um inibidor de receptor dopaminérgico d2, bem como o uso do preferido inibidor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9192605B2 (https=) |
| EP (1) | EP2459194A4 (https=) |
| JP (1) | JP5756105B2 (https=) |
| KR (1) | KR20120103557A (https=) |
| CN (1) | CN102548555A (https=) |
| AU (1) | AU2010278645A1 (https=) |
| BR (1) | BR112012008193A2 (https=) |
| CA (1) | CA2769149A1 (https=) |
| IL (1) | IL217149A0 (https=) |
| MX (1) | MX2012001290A (https=) |
| NZ (1) | NZ598247A (https=) |
| WO (1) | WO2011011886A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6154025B2 (ja) * | 2012-12-24 | 2017-06-28 | ニューロガストルクス，インコーポレイテッド | Ｇｉ管障害を治療するための方法 |
| JP6371716B2 (ja) * | 2014-04-01 | 2018-08-08 | 東京エレクトロン株式会社 | 基板液処理装置及び基板液処理方法並びに基板液処理プログラムを記録したコンピュータ読み取り可能な記録媒体 |
| WO2015200369A1 (en) | 2014-06-24 | 2015-12-30 | Neurogastrx, Inc. | Prodrugs of metopimazine |
| US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
| CN114601928B (zh) * | 2022-04-02 | 2023-03-17 | 首都医科大学 | 一种钙超载介导神经元死亡的标志物及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1219667B (it) * | 1988-06-21 | 1990-05-24 | Polifarma Spa | Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico |
| RU2057529C1 (ru) * | 1994-05-30 | 1996-04-10 | Алексей Михайлович Коршунов | Способ лечения синдрома паркинсонизма |
| US20010056101A1 (en) * | 1998-06-29 | 2001-12-27 | Carol A. Tamminga | Use of dopamine receptor antagonists in combination with partial dopamine agonist to prevent tolerance in treating nervous disorders related to dopamine dysfunction |
| DE10111486A1 (de) * | 2001-03-09 | 2002-10-02 | Ralph R Dawirs | Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit |
| ATE360415T1 (de) | 2002-09-17 | 2007-05-15 | Motac Neuroscience Ltd | Behandlung von dyskinesie |
| AU2003285928A1 (en) | 2002-10-22 | 2004-05-13 | Drugabuse Sciences S.A.S. | Treatment of cognitive impairment using a selective dopamine d1 receptor agonist |
| CA2628298A1 (en) * | 2004-11-03 | 2006-05-11 | Clera Inc. | Method to detect dopamine receptors in the functional d2high state |
| AU2009212065B2 (en) * | 2008-02-05 | 2014-03-20 | Clera Inc. | Compositions and methods for alleviating depression or improving cognition |
-
2010
- 2010-07-30 MX MX2012001290A patent/MX2012001290A/es unknown
- 2010-07-30 WO PCT/CA2010/001185 patent/WO2011011886A1/en not_active Ceased
- 2010-07-30 JP JP2012521920A patent/JP5756105B2/ja not_active Expired - Fee Related
- 2010-07-30 BR BR112012008193A patent/BR112012008193A2/pt not_active IP Right Cessation
- 2010-07-30 CA CA2769149A patent/CA2769149A1/en not_active Abandoned
- 2010-07-30 CN CN2010800342070A patent/CN102548555A/zh active Pending
- 2010-07-30 KR KR1020127005095A patent/KR20120103557A/ko not_active Ceased
- 2010-07-30 US US13/386,104 patent/US9192605B2/en not_active Expired - Fee Related
- 2010-07-30 AU AU2010278645A patent/AU2010278645A1/en not_active Abandoned
- 2010-07-30 EP EP10803783A patent/EP2459194A4/en not_active Withdrawn
- 2010-07-30 NZ NZ598247A patent/NZ598247A/en not_active IP Right Cessation
-
2011
- 2011-12-22 IL IL217149A patent/IL217149A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011011886A1 (en) | 2011-02-03 |
| EP2459194A1 (en) | 2012-06-06 |
| MX2012001290A (es) | 2012-06-12 |
| KR20120103557A (ko) | 2012-09-19 |
| CN102548555A (zh) | 2012-07-04 |
| IL217149A0 (en) | 2012-02-29 |
| JP2013500943A (ja) | 2013-01-10 |
| US9192605B2 (en) | 2015-11-24 |
| CA2769149A1 (en) | 2011-02-03 |
| US20120115910A1 (en) | 2012-05-10 |
| JP5756105B2 (ja) | 2015-07-29 |
| EP2459194A4 (en) | 2012-12-19 |
| NZ598247A (en) | 2014-01-31 |
| AU2010278645A1 (en) | 2012-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01532B (me) | Jedinjenja | |
| BRPI1013777A8 (pt) | Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. | |
| CY1120741T1 (el) | Θεραπεια οζωδους σκληρυνσης | |
| CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
| PA8772101A1 (es) | Imidazol-triazolopirimidinas sustituidas | |
| GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
| CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
| UY30573A1 (es) | N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2 | |
| BRPI1008060A2 (pt) | Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo. | |
| ECSP088835A (es) | Terapia combinatoria que involucra antagonistas de alfa5beta1 | |
| UY30829A1 (es) | Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato | |
| CL2011002056A1 (es) | Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras. | |
| DOP2013000036A (es) | Derivados de ciclobutano como inhibidores de jak | |
| PA8784101A1 (es) | Oxazolidinonas sustituidas y su uso | |
| CR20110100A (es) | Nuevos derivados de sulfamida sustituida | |
| CL2008002864A1 (es) | Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros. | |
| BRPI1015006A2 (pt) | uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas | |
| BRPI0912362A2 (pt) | antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos | |
| BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
| BR112013009004A2 (pt) | combinações de agonistas de receptor de serotonina para o tratamento de distúrbios de movimento | |
| BRPI0919231A2 (pt) | agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades | |
| MX354125B (es) | Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. | |
| NO20085099L (no) | Puritonderivativer som HM74A agonister | |
| CL2008002450A1 (es) | Compuestos derivados de fenil-pirrolidin-eter, con actividad antagonista de los receptores nk3; procedimientos para su preparacion; composicion farmaceutica; y el uso de los compuestos en el tratamiento de depresion, dolor, psicosis, entre otras. | |
| ECSP099675A (es) | Compuestos heterocíclicos, composición y métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |